S'abonner

A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women - 19/08/11

Doi : 10.1016/j.jaad.2006.09.025 
Iltefat Hamzavi, MD , Eileen Tan, MD, Jerry Shapiro, MD, FRCPC, Harvey Lui, MD, FRCPC
From the Department of Dermatology and Skin Science, University of British Columbia and the Vancouver Coastal Health Research Institute 

Reprint requests: Dr Harvey Lui, Professor and Chairman, Department of Dermatology and Skin Science, University of British Columbia, 835 W 10th Ave, Vancouver, BC, Canada V5Z 4E8.

Vancouver, British Columbia, Canada

Abstract

Background and Objective

Although there are a multitude of therapeutic modalities for removing unwanted facial hair in women, there is very little information on using the newer medical treatment approaches in combination. This study was designed to determine whether topical eflornithine can enhance the efficacy of laser hair removal.

Design

This was a randomized, double-blind, placebo-controlled, right-left comparison study of eflornithine cream combined with laser treatment versus laser alone for treating unwanted hair on the upper lip in women. All subjects underwent treatment to the entire upper lip with a long pulse alexandrite laser (10-40 ms pulse duration) at fluences of 7 to 40 J/cm2. Laser treatments were performed every 4 weeks for up to 6 sessions. Each patient also applied either eflornithine or placebo cream twice daily to each side of the upper lip in a double-blinded manner. Subjects were evaluated for safety by recording adverse events and for efficacy via (1) investigator global scoring, (2) patient self assessment, and (3) hair count analysis.

Results

Both treatment modalities were well tolerated by the 31 evaluable patients. All 3 outcome measures showed significantly better results in favor of eflornithine plus laser versus laser treatment alone. At the end of the study, complete or almost complete hair removal was achieved in 29 of 31 (93.5%) of the eflornithine-laser–treated sites versus 21 of 31 (67.9%) for the placebo cream-laser–treated sites (P = .021, McNemar test). Statistically significant differences in favor of eflornithine were likewise demonstrated at the final assessment through blinded patient grading (13/31 patients [41.9%] thought that the eflornithine was superior to placebo, P = .029, Poisson regression) and hair count analysis (P < .01, paired t test).

Limitations

This is a single-center study that did not determine whether the differences noted above last beyond 6 months.

Conclusions

On the basis of both investigator and patient assessments and hair count analysis, we have demonstrated that the addition of eflornithine to laser hair removal results in a more rapid and complete reduction of unwanted facial hair in women when the combination is used for up to 6 months.

Le texte complet de cet article est disponible en PDF.

Plan


 Funding sources: None.
Disclosures: Dr Lui has been a speaker for Barrier Therapeutics Canada. Dr Hamzavi has been a speaker for Shire Pharmaceuticals and SkinMedica. Dr Shapiro is a speaker for Shire Pharmaceuticals and Barrier Therapeutics Canada and has served as a consultant for SkinMedica.
Previously presented in part at the annual meeting of the American Society for Laser Medicine and Surgery, Anaheim, California, April 2003.


© 2007  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 57 - N° 1

P. 54-59 - juillet 2007 Retour au numéro
Article précédent Article précédent
  • A case-series of 29 patients with lichen planopilaris: The Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment
  • Nathaniel C. Cevasco, Wilma F. Bergfeld, Berna K. Remzi, Haydee Ramirez de Knott
| Article suivant Article suivant
  • Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001-2005
  • Matthew S. Goldberg, John T. Doucette, Henry W. Lim, James Spencer, John A. Carucci, Darrell S. Rigel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.